Mechanisms of action of fluvoxamine for COVID-19: a historical review

Y Hashimoto, T Suzuki, K Hashimoto - Molecular psychiatry, 2022 - nature.com
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of …

The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis

H Nakhaee, M Zangiabadian, R Bayati, M Rahmanian… - PLoS …, 2022 - journals.plos.org
Introduction Clinical Depression and the subsequent low immunity is a comorbidity that can
act as a risk factor for the severity of COVID-19 cases. Antidepressants such as Selective …

Association between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID‐19: an observational multicenter study

N Hoertel, M Sánchez‐Rico, E Gulbins… - Clinical …, 2021 - Wiley Online Library
Several medications commonly used for a number of medical conditions share a property of
functional inhibition of acid sphingomyelinase (ASM), or FIASMA. Preclinical and clinical …

Association between the use of psychotropic medications and the risk of COVID-19 infection among long-term inpatients with serious mental illness in a New York …

K Nemani, SZ Williams, M Olfson… - JAMA Network …, 2022 - jamanetwork.com
Importance Individuals with serious mental illness are at increased risk of severe COVID-19
infection. Several psychotropic medications have been identified as potential therapeutic …

Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2

BA Fritz, N Hoertel, EJ Lenze, F Jalali… - Translational …, 2022 - nature.com
Antidepressants have previously been associated with better outcomes in patients
hospitalized with COVID-19, but their effect on clinical deterioration among ambulatory …

Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort

CL Clelland, K Ramiah, L Steinberg, JD Clelland - BJPsych Open, 2022 - cambridge.org
BackgroundDuring the first wave of the coronavirus disease 2019 (COVID-19) pandemic,
patients with confirmed cases in New York State accounted for roughly 25% of total US …

Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study

BJ Kirenga, L Mugenyi, M Sánchez-Rico, H Kyobe… - Molecular …, 2023 - nature.com
Prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI)
used for the treatment of obsessive-compulsive disorder and major depressive disorder …

Observational study of haloperidol in hospitalized patients with COVID-19

N Hoertel, M Sánchez-Rico, R Vernet, AS Jannot… - PLoS …, 2021 - journals.plos.org
Background Haloperidol, a widely used antipsychotic, has been suggested as potentially
useful for patients with COVID-19 on the grounds of its in-vitro antiviral effects against SARS …

Medications modulating the acid sphingomyelinase/ceramide system and 28-day mortality among patients with SARS-CoV-2: an observational study

N Hoertel, K Rezaei, M Sánchez-Rico… - Pharmaceuticals, 2023 - mdpi.com
Prior evidence indicates the potential central role of the acid sphingomyelinase
(ASM)/ceramide system in the infection of cells with SARS-CoV-2. We conducted a …

[HTML][HTML] Drug repurposing for COVID-19 using graph neural network with genetic, mechanistic, and epidemiological validation

K Hsieh, Y Wang, L Chen, Z Zhao, S Savitz… - Research …, 2020 - ncbi.nlm.nih.gov
Amid the pandemic of 2019 novel coronavirus disease (COVID-19) infected by SARS-CoV-
2, a vast amount of drug research for prevention and treatment has been quickly conducted …